The research and wide application of EGFR-TKI (Tyrosine kinase inhibitors) drugs, mainly including Gefitinib, Erlotinib, Icotinib, Afatinib, Dasatinib, and Osimertinib, have greatly improved the overall survival of patients with lung cancer with the EGFR gene mutation. This evidence concerns the gene EGFR and lung cancer.